Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I randomized placebo-controlled study of GDC-0134 in amyotrophic lateral sclerosis
NL-OMON46763Phase 1Withdrawn
- Sponsor
- Genentech
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing GDC-0134 with Placebo (2 arms). Primary endpoints: Incidence, nature, and severity of all adverse events, Incidence and nature of laboratory abnormalities and 2 more. Planned start Oct 2017; status: withdrawn.
02
Drugs
GDC-0134
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON46763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46763.